CN114181918A - 一种通过DNA合成改组组合突变获得的ω-转氨酶突变体及应用 - Google Patents
一种通过DNA合成改组组合突变获得的ω-转氨酶突变体及应用 Download PDFInfo
- Publication number
- CN114181918A CN114181918A CN202111345072.6A CN202111345072A CN114181918A CN 114181918 A CN114181918 A CN 114181918A CN 202111345072 A CN202111345072 A CN 202111345072A CN 114181918 A CN114181918 A CN 114181918A
- Authority
- CN
- China
- Prior art keywords
- artificial sequence
- transaminase
- mutant
- mutation
- enzyme
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000035772 mutation Effects 0.000 title claims abstract description 30
- 230000006820 DNA synthesis Effects 0.000 title claims abstract description 13
- 241001465318 Aspergillus terreus Species 0.000 claims abstract description 16
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 2
- 108090000623 proteins and genes Proteins 0.000 claims description 33
- KWOLFJPFCHCOCG-UHFFFAOYSA-N Acetophenone Chemical compound CC(=O)C1=CC=CC=C1 KWOLFJPFCHCOCG-UHFFFAOYSA-N 0.000 claims description 14
- 238000006243 chemical reaction Methods 0.000 claims description 11
- RQEUFEKYXDPUSK-SSDOTTSWSA-N (1R)-1-phenylethanamine Chemical compound C[C@@H](N)C1=CC=CC=C1 RQEUFEKYXDPUSK-SSDOTTSWSA-N 0.000 claims description 10
- 239000002773 nucleotide Substances 0.000 claims description 10
- 125000003729 nucleotide group Chemical group 0.000 claims description 10
- 241000894006 Bacteria Species 0.000 claims description 6
- 230000015572 biosynthetic process Effects 0.000 claims description 5
- 238000003259 recombinant expression Methods 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000013613 expression plasmid Substances 0.000 claims description 2
- 239000013604 expression vector Substances 0.000 claims description 2
- 108090000790 Enzymes Proteins 0.000 abstract description 68
- 102000004190 Enzymes Human genes 0.000 abstract description 67
- 238000000034 method Methods 0.000 abstract description 20
- 238000002474 experimental method Methods 0.000 abstract description 4
- 229940088598 enzyme Drugs 0.000 description 65
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 30
- 239000000243 solution Substances 0.000 description 28
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 23
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
- 239000013615 primer Substances 0.000 description 18
- 239000007788 liquid Substances 0.000 description 17
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 16
- 230000000694 effects Effects 0.000 description 15
- 239000000047 product Substances 0.000 description 14
- NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 description 13
- 102000004169 proteins and genes Human genes 0.000 description 12
- 102000003929 Transaminases Human genes 0.000 description 11
- 108090000340 Transaminases Proteins 0.000 description 11
- 239000013612 plasmid Substances 0.000 description 11
- 235000018102 proteins Nutrition 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 239000000872 buffer Substances 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 239000012528 membrane Substances 0.000 description 9
- 238000012216 screening Methods 0.000 description 9
- 239000000758 substrate Substances 0.000 description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- 238000012408 PCR amplification Methods 0.000 description 8
- 238000001962 electrophoresis Methods 0.000 description 8
- 239000000499 gel Substances 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 8
- 150000001412 amines Chemical class 0.000 description 7
- 239000008367 deionised water Substances 0.000 description 7
- 229910021641 deionized water Inorganic materials 0.000 description 7
- 238000010438 heat treatment Methods 0.000 description 7
- 235000007682 pyridoxal 5'-phosphate Nutrition 0.000 description 7
- 239000011589 pyridoxal 5'-phosphate Substances 0.000 description 7
- 229960001327 pyridoxal phosphate Drugs 0.000 description 7
- 239000013598 vector Substances 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 241000588724 Escherichia coli Species 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 6
- -1 amine compounds Chemical class 0.000 description 6
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 6
- 229960000723 ampicillin Drugs 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 6
- 238000004925 denaturation Methods 0.000 description 6
- 230000036425 denaturation Effects 0.000 description 6
- 238000009510 drug design Methods 0.000 description 6
- 239000012149 elution buffer Substances 0.000 description 6
- 229930027917 kanamycin Natural products 0.000 description 6
- 229960000318 kanamycin Drugs 0.000 description 6
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 6
- 229930182823 kanamycin A Natural products 0.000 description 6
- 235000019799 monosodium phosphate Nutrition 0.000 description 6
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 6
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 6
- 150000001413 amino acids Chemical group 0.000 description 5
- 230000003197 catalytic effect Effects 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 5
- 230000002441 reversible effect Effects 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 229910021642 ultra pure water Inorganic materials 0.000 description 5
- 239000012498 ultrapure water Substances 0.000 description 5
- 241001052560 Thallis Species 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 229940024606 amino acid Drugs 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 239000013599 cloning vector Substances 0.000 description 4
- 239000005515 coenzyme Substances 0.000 description 4
- 235000018417 cysteine Nutrition 0.000 description 4
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 4
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 4
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 4
- 229930182817 methionine Natural products 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 229960000583 acetic acid Drugs 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000000137 annealing Methods 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 238000007710 freezing Methods 0.000 description 3
- 230000008014 freezing Effects 0.000 description 3
- 239000012362 glacial acetic acid Substances 0.000 description 3
- 239000005457 ice water Substances 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000012474 protein marker Substances 0.000 description 3
- ZMJGSOSNSPKHNH-UHFFFAOYSA-N pyridoxamine 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(CN)=C1O ZMJGSOSNSPKHNH-UHFFFAOYSA-N 0.000 description 3
- 235000008974 pyridoxamine 5'-phosphate Nutrition 0.000 description 3
- 239000011580 pyridoxamine 5'-phosphate Substances 0.000 description 3
- 229940107700 pyruvic acid Drugs 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- AXXCUABIFZPKPM-BQBZGAKWSA-N Asp-Arg-Gly Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O AXXCUABIFZPKPM-BQBZGAKWSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 239000003155 DNA primer Substances 0.000 description 2
- 101710088194 Dehydrogenase Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 101710164401 Omega-aminotransferase Proteins 0.000 description 2
- MWPYEGWZVKXNTJ-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine hydrate tetrahydrochloride Chemical compound O.Cl.Cl.Cl.Cl.NNc1ccc(cc1)-c1ccc(NN)cc1 MWPYEGWZVKXNTJ-UHFFFAOYSA-N 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000002022 differential scanning fluorescence spectroscopy Methods 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 108010078144 glutaminyl-glycine Proteins 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 210000001082 somatic cell Anatomy 0.000 description 2
- 239000012192 staining solution Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000010257 thawing Methods 0.000 description 2
- 238000005891 transamination reaction Methods 0.000 description 2
- HSTOKWSFWGCZMH-UHFFFAOYSA-N 3,3'-diaminobenzidine Chemical compound C1=C(N)C(N)=CC=C1C1=CC=C(N)C(N)=C1 HSTOKWSFWGCZMH-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- QDRGPQWIVZNJQD-CIUDSAMLSA-N Ala-Arg-Gln Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(O)=O QDRGPQWIVZNJQD-CIUDSAMLSA-N 0.000 description 1
- FUSPCLTUKXQREV-ACZMJKKPSA-N Ala-Glu-Ala Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O FUSPCLTUKXQREV-ACZMJKKPSA-N 0.000 description 1
- VGPWRRFOPXVGOH-BYPYZUCNSA-N Ala-Gly-Gly Chemical compound C[C@H](N)C(=O)NCC(=O)NCC(O)=O VGPWRRFOPXVGOH-BYPYZUCNSA-N 0.000 description 1
- KMGOBAQSCKTBGD-DLOVCJGASA-N Ala-His-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](C)N)CC1=CN=CN1 KMGOBAQSCKTBGD-DLOVCJGASA-N 0.000 description 1
- MAEQBGQTDWDSJQ-LSJOCFKGSA-N Ala-Met-His Chemical compound C[C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N MAEQBGQTDWDSJQ-LSJOCFKGSA-N 0.000 description 1
- CREYEAPXISDKSB-FQPOAREZSA-N Ala-Thr-Tyr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O CREYEAPXISDKSB-FQPOAREZSA-N 0.000 description 1
- MTDDMSUUXNQMKK-BPNCWPANSA-N Ala-Tyr-Arg Chemical compound C[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N MTDDMSUUXNQMKK-BPNCWPANSA-N 0.000 description 1
- QRIYOHQJRDHFKF-UWJYBYFXSA-N Ala-Tyr-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)C)CC1=CC=C(O)C=C1 QRIYOHQJRDHFKF-UWJYBYFXSA-N 0.000 description 1
- 244000153158 Ammi visnaga Species 0.000 description 1
- 235000010585 Ammi visnaga Nutrition 0.000 description 1
- SYAUZLVLXCDRSH-IUCAKERBSA-N Arg-Gly-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CCCN=C(N)N)N SYAUZLVLXCDRSH-IUCAKERBSA-N 0.000 description 1
- GNYUVVJYGJFKHN-RVMXOQNASA-N Arg-Ile-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N GNYUVVJYGJFKHN-RVMXOQNASA-N 0.000 description 1
- LVMUGODRNHFGRA-AVGNSLFASA-N Arg-Leu-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O LVMUGODRNHFGRA-AVGNSLFASA-N 0.000 description 1
- YKZJPIPFKGYHKY-DCAQKATOSA-N Arg-Leu-Asp Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O YKZJPIPFKGYHKY-DCAQKATOSA-N 0.000 description 1
- SPCONPVIDFMDJI-QSFUFRPTSA-N Asn-Ile-Val Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(O)=O SPCONPVIDFMDJI-QSFUFRPTSA-N 0.000 description 1
- TZFQICWZWFNIKU-KKUMJFAQSA-N Asn-Leu-Tyr Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 TZFQICWZWFNIKU-KKUMJFAQSA-N 0.000 description 1
- TVIZQBFURPLQDV-DJFWLOJKSA-N Asp-His-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@H](CC(=O)O)N TVIZQBFURPLQDV-DJFWLOJKSA-N 0.000 description 1
- QNMKWNONJGKJJC-NHCYSSNCSA-N Asp-Leu-Val Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O QNMKWNONJGKJJC-NHCYSSNCSA-N 0.000 description 1
- QPDUWAUSSWGJSB-NGZCFLSTSA-N Asp-Val-Pro Chemical compound CC(C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC(=O)O)N QPDUWAUSSWGJSB-NGZCFLSTSA-N 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- GSNRZJNHMVMOFV-ACZMJKKPSA-N Cys-Asp-Glu Chemical compound C(CC(=O)O)[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CS)N GSNRZJNHMVMOFV-ACZMJKKPSA-N 0.000 description 1
- IRKLTAKLAFUTLA-KATARQTJSA-N Cys-Thr-Lys Chemical compound C[C@@H](O)[C@H](NC(=O)[C@@H](N)CS)C(=O)N[C@@H](CCCCN)C(O)=O IRKLTAKLAFUTLA-KATARQTJSA-N 0.000 description 1
- NAPULYCVEVVFRB-HEIBUPTGSA-N Cys-Thr-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](N)CS NAPULYCVEVVFRB-HEIBUPTGSA-N 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- FTIJVMLAGRAYMJ-MNXVOIDGSA-N Gln-Ile-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](N)CCC(N)=O FTIJVMLAGRAYMJ-MNXVOIDGSA-N 0.000 description 1
- RGNMNWULPAYDAH-JSGCOSHPSA-N Gln-Trp-Gly Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](CCC(=O)N)N RGNMNWULPAYDAH-JSGCOSHPSA-N 0.000 description 1
- MKRDNSWGJWTBKZ-GVXVVHGQSA-N Gln-Val-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCC(=O)N)N MKRDNSWGJWTBKZ-GVXVVHGQSA-N 0.000 description 1
- RUFHOVYUYSNDNY-ACZMJKKPSA-N Glu-Ala-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCC(O)=O RUFHOVYUYSNDNY-ACZMJKKPSA-N 0.000 description 1
- MXOODARRORARSU-ACZMJKKPSA-N Glu-Ala-Ser Chemical compound C[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CCC(=O)O)N MXOODARRORARSU-ACZMJKKPSA-N 0.000 description 1
- KXTAGESXNQEZKB-DZKIICNBSA-N Glu-Phe-Val Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](C(C)C)C(O)=O)CC1=CC=CC=C1 KXTAGESXNQEZKB-DZKIICNBSA-N 0.000 description 1
- UDEPRBFQTWGLCW-CIUDSAMLSA-N Glu-Pro-Asp Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(O)=O)C(O)=O UDEPRBFQTWGLCW-CIUDSAMLSA-N 0.000 description 1
- KRRMJKMGWWXWDW-STQMWFEESA-N Gly-Arg-Phe Chemical compound NC(=N)NCCC[C@H](NC(=O)CN)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 KRRMJKMGWWXWDW-STQMWFEESA-N 0.000 description 1
- YYPFZVIXAVDHIK-IUCAKERBSA-N Gly-Glu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CN YYPFZVIXAVDHIK-IUCAKERBSA-N 0.000 description 1
- QPTNELDXWKRIFX-YFKPBYRVSA-N Gly-Gly-Gln Chemical compound NCC(=O)NCC(=O)N[C@H](C(O)=O)CCC(N)=O QPTNELDXWKRIFX-YFKPBYRVSA-N 0.000 description 1
- SWQALSGKVLYKDT-UHFFFAOYSA-N Gly-Ile-Ala Natural products NCC(=O)NC(C(C)CC)C(=O)NC(C)C(O)=O SWQALSGKVLYKDT-UHFFFAOYSA-N 0.000 description 1
- MXIULRKNFSCJHT-STQMWFEESA-N Gly-Phe-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CC=CC=C1 MXIULRKNFSCJHT-STQMWFEESA-N 0.000 description 1
- YXTFLTJYLIAZQG-FJXKBIBVSA-N Gly-Thr-Arg Chemical compound NCC(=O)N[C@@H]([C@H](O)C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N YXTFLTJYLIAZQG-FJXKBIBVSA-N 0.000 description 1
- UIQGJYUEQDOODF-KWQFWETISA-N Gly-Tyr-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)CN)CC1=CC=C(O)C=C1 UIQGJYUEQDOODF-KWQFWETISA-N 0.000 description 1
- JYGYNWYVKXENNE-OALUTQOASA-N Gly-Tyr-Trp Chemical compound [H]NCC(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O JYGYNWYVKXENNE-OALUTQOASA-N 0.000 description 1
- BAYQNCWLXIDLHX-ONGXEEELSA-N Gly-Val-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)CN BAYQNCWLXIDLHX-ONGXEEELSA-N 0.000 description 1
- AFMOTCMSEBITOE-YEPSODPASA-N Gly-Val-Thr Chemical compound NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O AFMOTCMSEBITOE-YEPSODPASA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- STGQSBKUYSPPIG-CIUDSAMLSA-N His-Ser-Asp Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC1=CN=CN1 STGQSBKUYSPPIG-CIUDSAMLSA-N 0.000 description 1
- GQKSJYINYYWPMR-NGZCFLSTSA-N Ile-Gly-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)NCC(=O)N1CCC[C@@H]1C(=O)O)N GQKSJYINYYWPMR-NGZCFLSTSA-N 0.000 description 1
- HUORUFRRJHELPD-MNXVOIDGSA-N Ile-Leu-Glu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N HUORUFRRJHELPD-MNXVOIDGSA-N 0.000 description 1
- FTUZWJVSNZMLPI-RVMXOQNASA-N Ile-Met-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCSC)C(=O)N1CCC[C@@H]1C(=O)O)N FTUZWJVSNZMLPI-RVMXOQNASA-N 0.000 description 1
- RENBRDSDKPSRIH-HJWJTTGWSA-N Ile-Phe-Met Chemical compound N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCSC)C(=O)O RENBRDSDKPSRIH-HJWJTTGWSA-N 0.000 description 1
- QGXQHJQPAPMACW-PPCPHDFISA-N Ile-Thr-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)O)N QGXQHJQPAPMACW-PPCPHDFISA-N 0.000 description 1
- NURNJECQNNCRBK-FLBSBUHZSA-N Ile-Thr-Thr Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O NURNJECQNNCRBK-FLBSBUHZSA-N 0.000 description 1
- ZYVTXBXHIKGZMD-QSFUFRPTSA-N Ile-Val-Asn Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(=O)N)C(=O)O)N ZYVTXBXHIKGZMD-QSFUFRPTSA-N 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- HGCNKOLVKRAVHD-UHFFFAOYSA-N L-Met-L-Phe Natural products CSCCC(N)C(=O)NC(C(O)=O)CC1=CC=CC=C1 HGCNKOLVKRAVHD-UHFFFAOYSA-N 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- LZDNBBYBDGBADK-UHFFFAOYSA-N L-valyl-L-tryptophan Natural products C1=CC=C2C(CC(NC(=O)C(N)C(C)C)C(O)=O)=CNC2=C1 LZDNBBYBDGBADK-UHFFFAOYSA-N 0.000 description 1
- 239000012880 LB liquid culture medium Substances 0.000 description 1
- PJYSOYLLTJKZHC-GUBZILKMSA-N Leu-Asp-Gln Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CCC(N)=O PJYSOYLLTJKZHC-GUBZILKMSA-N 0.000 description 1
- ULXYQAJWJGLCNR-YUMQZZPRSA-N Leu-Asp-Gly Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(O)=O ULXYQAJWJGLCNR-YUMQZZPRSA-N 0.000 description 1
- KWLWZYMNUZJKMZ-IHRRRGAJSA-N Leu-Pro-Leu Chemical compound CC(C)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(O)=O KWLWZYMNUZJKMZ-IHRRRGAJSA-N 0.000 description 1
- HGLKOTPFWOMPOB-MEYUZBJRSA-N Leu-Thr-Tyr Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 HGLKOTPFWOMPOB-MEYUZBJRSA-N 0.000 description 1
- FBNPMTNBFFAMMH-UHFFFAOYSA-N Leu-Val-Arg Natural products CC(C)CC(N)C(=O)NC(C(C)C)C(=O)NC(C(O)=O)CCCN=C(N)N FBNPMTNBFFAMMH-UHFFFAOYSA-N 0.000 description 1
- YQFZRHYZLARWDY-IHRRRGAJSA-N Leu-Val-Lys Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CCCCN YQFZRHYZLARWDY-IHRRRGAJSA-N 0.000 description 1
- FACUGMGEFUEBTI-SRVKXCTJSA-N Lys-Asn-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CCCCN FACUGMGEFUEBTI-SRVKXCTJSA-N 0.000 description 1
- DTUZCYRNEJDKSR-NHCYSSNCSA-N Lys-Gly-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN DTUZCYRNEJDKSR-NHCYSSNCSA-N 0.000 description 1
- GFWLIJDQILOEPP-HSCHXYMDSA-N Lys-Ile-Trp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)NC(=O)[C@H](CCCCN)N GFWLIJDQILOEPP-HSCHXYMDSA-N 0.000 description 1
- WXHHTBVYQOSYSL-FXQIFTODSA-N Met-Ala-Ser Chemical compound CSCC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O WXHHTBVYQOSYSL-FXQIFTODSA-N 0.000 description 1
- WGBMNLCRYKSWAR-DCAQKATOSA-N Met-Asp-Lys Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CCCCN WGBMNLCRYKSWAR-DCAQKATOSA-N 0.000 description 1
- OXHSZBRPUGNMKW-DCAQKATOSA-N Met-Gln-Arg Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O OXHSZBRPUGNMKW-DCAQKATOSA-N 0.000 description 1
- HUURTRNKPBHHKZ-JYJNAYRXSA-N Met-Phe-Val Chemical compound CSCC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](C(C)C)C(O)=O)CC1=CC=CC=C1 HUURTRNKPBHHKZ-JYJNAYRXSA-N 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- YBAFDPFAUTYYRW-UHFFFAOYSA-N N-L-alpha-glutamyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CCC(O)=O YBAFDPFAUTYYRW-UHFFFAOYSA-N 0.000 description 1
- 108010079364 N-glycylalanine Proteins 0.000 description 1
- 108010066427 N-valyltryptophan Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- MGECUMGTSHYHEJ-QEWYBTABSA-N Phe-Glu-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 MGECUMGTSHYHEJ-QEWYBTABSA-N 0.000 description 1
- SSSFPISOZOLQNP-GUBZILKMSA-N Pro-Arg-Asp Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(O)=O SSSFPISOZOLQNP-GUBZILKMSA-N 0.000 description 1
- MGDFPGCFVJFITQ-CIUDSAMLSA-N Pro-Glu-Asp Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O MGDFPGCFVJFITQ-CIUDSAMLSA-N 0.000 description 1
- ZUZINZIJHJFJRN-UBHSHLNASA-N Pro-Phe-Ala Chemical compound C([C@@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H]1NCCC1)C1=CC=CC=C1 ZUZINZIJHJFJRN-UBHSHLNASA-N 0.000 description 1
- WHNJMTHJGCEKGA-ULQDDVLXSA-N Pro-Phe-Leu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(O)=O WHNJMTHJGCEKGA-ULQDDVLXSA-N 0.000 description 1
- CXGLFEOYCJFKPR-RCWTZXSCSA-N Pro-Thr-Val Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O CXGLFEOYCJFKPR-RCWTZXSCSA-N 0.000 description 1
- FIDNSJUXESUDOV-JYJNAYRXSA-N Pro-Tyr-Val Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C(C)C)C(O)=O FIDNSJUXESUDOV-JYJNAYRXSA-N 0.000 description 1
- ZAUHSLVPDLNTRZ-QXEWZRGKSA-N Pro-Val-Asn Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O ZAUHSLVPDLNTRZ-QXEWZRGKSA-N 0.000 description 1
- IMNVAOPEMFDAQD-NHCYSSNCSA-N Pro-Val-Glu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O IMNVAOPEMFDAQD-NHCYSSNCSA-N 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 244000088415 Raphanus sativus Species 0.000 description 1
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 239000002262 Schiff base Substances 0.000 description 1
- 150000004753 Schiff bases Chemical class 0.000 description 1
- IOVHBRCQOGWAQH-ZKWXMUAHSA-N Ser-Gly-Ile Chemical compound [H]N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(O)=O IOVHBRCQOGWAQH-ZKWXMUAHSA-N 0.000 description 1
- JFWDJFULOLKQFY-QWRGUYRKSA-N Ser-Gly-Phe Chemical compound [H]N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O JFWDJFULOLKQFY-QWRGUYRKSA-N 0.000 description 1
- KKKVOZNCLALMPV-XKBZYTNZSA-N Ser-Thr-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(O)=O KKKVOZNCLALMPV-XKBZYTNZSA-N 0.000 description 1
- VFEHSAJCWWHDBH-RHYQMDGZSA-N Thr-Arg-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(O)=O VFEHSAJCWWHDBH-RHYQMDGZSA-N 0.000 description 1
- JEDIEMIJYSRUBB-FOHZUACHSA-N Thr-Asp-Gly Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(O)=O JEDIEMIJYSRUBB-FOHZUACHSA-N 0.000 description 1
- SHOMROOOQBDGRL-JHEQGTHGSA-N Thr-Glu-Gly Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O SHOMROOOQBDGRL-JHEQGTHGSA-N 0.000 description 1
- AAZOYLQUEQRUMZ-GSSVUCPTSA-N Thr-Thr-Asn Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CC(N)=O AAZOYLQUEQRUMZ-GSSVUCPTSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- LNGFWVPNKLWATF-ZVZYQTTQSA-N Trp-Val-Glu Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O LNGFWVPNKLWATF-ZVZYQTTQSA-N 0.000 description 1
- KPEVFMGKBCMTJF-SZMVWBNQSA-N Trp-Val-Met Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCSC)C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)N KPEVFMGKBCMTJF-SZMVWBNQSA-N 0.000 description 1
- PEVVXUGSAKEPEN-AVGNSLFASA-N Tyr-Asn-Glu Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O PEVVXUGSAKEPEN-AVGNSLFASA-N 0.000 description 1
- GAYLGYUVTDMLKC-UWJYBYFXSA-N Tyr-Asp-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 GAYLGYUVTDMLKC-UWJYBYFXSA-N 0.000 description 1
- AOIZTZRWMSPPAY-KAOXEZKKSA-N Tyr-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC2=CC=C(C=C2)O)N)O AOIZTZRWMSPPAY-KAOXEZKKSA-N 0.000 description 1
- RUCNAYOMFXRIKJ-DCAQKATOSA-N Val-Ala-Lys Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCCCN RUCNAYOMFXRIKJ-DCAQKATOSA-N 0.000 description 1
- MHAHQDBEIDPFQS-NHCYSSNCSA-N Val-Glu-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)C(C)C MHAHQDBEIDPFQS-NHCYSSNCSA-N 0.000 description 1
- PIFJAFRUVWZRKR-QMMMGPOBSA-N Val-Gly-Gly Chemical compound CC(C)[C@H]([NH3+])C(=O)NCC(=O)NCC([O-])=O PIFJAFRUVWZRKR-QMMMGPOBSA-N 0.000 description 1
- HGJRMXOWUWVUOA-GVXVVHGQSA-N Val-Leu-Gln Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](C(C)C)N HGJRMXOWUWVUOA-GVXVVHGQSA-N 0.000 description 1
- LJSZPMSUYKKKCP-UBHSHLNASA-N Val-Phe-Ala Chemical compound CC(C)[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](C)C(O)=O)CC1=CC=CC=C1 LJSZPMSUYKKKCP-UBHSHLNASA-N 0.000 description 1
- NHXZRXLFOBFMDM-AVGNSLFASA-N Val-Pro-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)C(C)C NHXZRXLFOBFMDM-AVGNSLFASA-N 0.000 description 1
- SUGRIIAOLCDLBD-ZOBUZTSGSA-N Val-Trp-Asp Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(=O)O)C(=O)O)N SUGRIIAOLCDLBD-ZOBUZTSGSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 108010076324 alanyl-glycyl-glycine Proteins 0.000 description 1
- 108010047495 alanylglycine Proteins 0.000 description 1
- 150000004705 aldimines Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 108010060035 arginylproline Proteins 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 108010077245 asparaginyl-proline Proteins 0.000 description 1
- 108010040443 aspartyl-aspartic acid Proteins 0.000 description 1
- 108010047857 aspartylglycine Proteins 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 238000007845 assembly PCR Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000011942 biocatalyst Substances 0.000 description 1
- 230000002210 biocatalytic effect Effects 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000012501 chromatography medium Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000007398 colorimetric assay Methods 0.000 description 1
- 238000002742 combinatorial mutagenesis Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 239000003712 decolorant Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 108010054813 diprotin B Proteins 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 1
- 108010037850 glycylvaline Proteins 0.000 description 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- OOYGSFOGFJDDHP-KMCOLRRFSA-N kanamycin A sulfate Chemical compound OS(O)(=O)=O.O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N OOYGSFOGFJDDHP-KMCOLRRFSA-N 0.000 description 1
- 229960002064 kanamycin sulfate Drugs 0.000 description 1
- 150000004715 keto acids Chemical class 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 108010057821 leucylproline Proteins 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 108010054155 lysyllysine Proteins 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 108010016686 methionyl-alanyl-serine Proteins 0.000 description 1
- 108010056582 methionylglutamic acid Proteins 0.000 description 1
- 108010068488 methionylphenylalanine Proteins 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000000329 molecular dynamics simulation Methods 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000001048 orange dye Substances 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 108010074082 phenylalanyl-alanyl-lysine Proteins 0.000 description 1
- 108010073025 phenylalanylphenylalanine Proteins 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 108010031719 prolyl-serine Proteins 0.000 description 1
- 108010015796 prolylisoleucine Proteins 0.000 description 1
- 108010090894 prolylleucine Proteins 0.000 description 1
- 229940076788 pyruvate Drugs 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 229910052703 rhodium Inorganic materials 0.000 description 1
- 239000010948 rhodium Substances 0.000 description 1
- MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium atom Chemical compound [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 229910052707 ruthenium Inorganic materials 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 230000000707 stereoselective effect Effects 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 238000005979 thermal decomposition reaction Methods 0.000 description 1
- 238000012932 thermodynamic analysis Methods 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 150000003624 transition metals Chemical class 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 239000012137 tryptone Substances 0.000 description 1
- 108010020532 tyrosyl-proline Proteins 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 108010073969 valyllysine Proteins 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 108010027345 wheylin-1 peptide Proteins 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1096—Transferases (2.) transferring nitrogenous groups (2.6)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
- C12N15/1031—Mutagenizing nucleic acids mutagenesis by gene assembly, e.g. assembly by oligonucleotide extension PCR
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/24—Preparation of oxygen-containing organic compounds containing a carbonyl group
- C12P7/26—Ketones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y206/00—Transferases transferring nitrogenous groups (2.6)
- C12Y206/01—Transaminases (2.6.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y206/00—Transferases transferring nitrogenous groups (2.6)
- C12Y206/01—Transaminases (2.6.1)
- C12Y206/01018—Beta-alanine-pyruvate transaminase (2.6.1.18)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
- C12N15/1027—Mutagenizing nucleic acids by DNA shuffling, e.g. RSR, STEP, RPR
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/185—Escherichia
- C12R2001/19—Escherichia coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/645—Fungi ; Processes using fungi
- C12R2001/66—Aspergillus
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/584—Recycling of catalysts
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Crystallography & Structural Chemistry (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
本发明公开了一种通过DNA合成改组组合突变获得的ω‑转氨酶突变体,由来自土曲霉(Aspergillus terreus)的野生型ω‑转氨酶进行点突变而得,野生型ω‑转氨酶的氨基酸序列如SEQ ID No.1所示,所述ω‑转氨酶突变体的突变位点为:F115L‑H210N。本发明通过DNA合成改组组合突变方法,将前期所得到的正向突变随机组合,通过实验验证,该方法可有效地提高正突变概率,提高实验效率及可行性,并筛选得到热力学稳定性明显优于野生酶的突变酶。
Description
技术领域
本发明涉及生物技术领域,特别是涉及一种通过DNA合成改组组合突变获得的ω-转氨酶突变体及应用。
背景技术
手性胺是很多重要药物合成的关键中间体或者手性砌块。目前,这些重要的手性胺化合物的生产方式主要为化学合成法,且一般需要昂贵的钌、铑等过渡金属配合物催化剂或高压等极端反应条件,同时存在选择性差、收率低、排放多等先天不足。因此,能否通过不对称生物催化的方法实现手性胺的工业化生产已成为目前研究者普遍关注的焦点。利用酶催化不对称合成手性胺类化合物主要应用两种酶,一种是氨基脱氢酶,一种是ω-转氨酶。利用氨基脱氢酶前提是要有与之相适应的辅酶再生体系。而ω-转氨酶依赖辅酶磷酸吡哆醛(PLP)可逆地催化氨基转移到前手性酮制备手性胺类化合物,因其高立体选择性和温和的反应条件,成为制备光学纯手性胺的重要生物催化剂。
ω-转氨酶催化过程是由两步半转胺反应组成,遵循双底物乒乓机制,如图1所示,在第一个半反应中,氨基供体底物和辅酶形成一个席夫碱(醛亚胺),醛亚胺经过进一步质子得失以及将氨基转移给辅酶,结果就得到酮酸和酶结合的5’-磷酸吡哆胺(PMP)。在第二个半反应中,氨基由PMP转移到受体上,得到PLP并且产生了手性胺。
来自于土曲霉(Aspergillus terreus)的ω-转氨酶以酮类化合物为原料,通过立体选择性地转氨基作用,可以高效生产手性胺。研究表明,该酶野生型在40℃下的半衰期仅为6.9min,其热稳定性有待进一步提高。如CN105441404A、CN105950581A公开了利用定点突变技术对ω-转氨酶野生型进行改造,获得热稳定性进一步提高的ω-转氨酶突变体,使其更适合工业应用。
目前,酶的定向进化技术是一种不需事先了解酶的空间结构和催化机制,人为地创造特殊的进化条件,模拟自然进化机制,在体外改造酶基因,并定向选择或筛选出所需性能更加优良的酶或创造出自然界所没有且优良性质的新酶的方法。近年来,随着定向进化技术的建立与发展,通过它提高酶稳定性的研究越来越多。主要包括非理性设计,理性设计和半理性设计三大块。随着相关研究的深入,利用半理性设计策略对转氨酶进行分子改造的研究备受关注。
本发明申请人一直致力于转氨酶催化合成手性胺方面的工作。通过半理性设计方法对转氨酶进行改造,主要包括添加二硫键(基于结构的半理性设计),序列一致性(基于序列的半理性设计)以及构建共进化网络来改造转氨酶的热稳定性并获得了一定的提升。但提高转氨酶热稳定性的各种手段均具有各自的优点和缺点,虽然上述实验获得的突变体与野生型ω-转氨酶相比能够提高半失活温度以及延长半衰期,但是若要在实际生产中更好地加以应用,上述突变体的半失活温度和半衰期仍有待进一步提高。
发明内容
本发明基于一种DNA合成改组的方法,通过该方法获得酶活、热稳定性进一步提高的土曲霉属(Aspergillus terreus)ω-转氨酶突变体。
本发明通过固体平板筛选结合96孔板筛选,大大提高了筛选效率和筛选数量。
本发明首先提供了一种通过DNA合成改组组合突变获得的ω-转氨酶突变体,其特征在于,由来自土曲霉(Aspergillus terreus)的野生型ω-转氨酶进行DNA合成改组的方法而得,野生型ω-转氨酶的氨基酸序列如SEQ ID No.1所示,所述ω-转氨酶突变体的突变位点为以下任意一种:(1)F115L-H210N-M150C-M280C;(2)F115L-H210N;(3)F115L-H210N-E253A-I295V;(4)I77L-F115L-E133A-H210N-N245D;(5)I77L-Q97E-F115L-L118T-E253A-G292D;(6)I77L-E133A-N245D-G292D;(7)H210N-N245D-E253A-G292D。上述突变体中突变位点为多个位点的突变形式,比如(1)F115L-H210N-M150C-M280C表示第115位的氨基酸由苯丙氨酸突变为亮氨酸、第210位的氨基酸由组氨酸突变为天冬酰胺、第150位的氨基酸由甲硫氨酸突变为半胱氨酸以及第280位的氨基酸由甲硫氨酸突变为半胱氨酸,该突变体的半失活温度为52.2℃,比野生型ω-转氨酶提高了13.7℃,在40℃下的半衰期为172.7min,比野生型ω-转氨酶延长165.8min。野生型ω-转氨酶基因的核苷酸序列如SEQ ID No.2所示。
本发明又公开了所述的ω-转氨酶突变体在催化(R)-(+)-α-甲基苄胺生成苯乙酮中的应用。
本发明又公开了编码所述ω-转氨酶突变体的基因。优选的,所述的基因,核苷酸序列如SEQ ID No.3~9。突变体F115L-H210N-M150C-M280C的核苷酸序列如SEQ ID NO.3所示;突变体F115L-H210N的核苷酸序列如SEQ ID NO.4所示;突变体F115L-H210N-E253A-I295V的核苷酸序列如SEQ ID NO.5所示;突变体I77L-F115L-E133A-H210N-N245D的核苷酸序列如SEQ ID NO.6所示;突变体I77L-Q97E-F115L-L118T-E253A-G292D的核苷酸序列如SEQ ID NO.7所示;突变体I77L-E133A-N245D-G292D的核苷酸序列如SEQ ID NO.8所示;突变体H210N-N245D-E253A-G292D的核苷酸序列如SEQ ID NO.9所示。
本发明又公开了所述基因在催化(R)-(+)-α-甲基苄胺生成苯乙酮中的应用。
本发明还公开了包含所述基因的重组表达载体。
本发明还公开了包含所述重组表达质粒的基因工程菌。
本发明还公开了所述基因工程菌在催化(R)-(+)-α-甲基苄胺生成苯乙酮中的应用。
与现有技术相比,本发明具有以下有益效果:(1)本发明ω-转氨酶突变体由土曲霉(Aspergillus terreus)ω-转氨酶115位的苯丙氨酸、150位的甲硫氨酸、210位的组氨酸和280位的甲硫氨酸分别突变为亮氨酸、半胱氨酸、天冬酰胺和半胱氨酸获得,该ω-转氨酶突变体的半失活温度(T50 10)为52.2±0.42℃,比野生型提高了13.7℃,在40℃下的半衰期(t1/2)为172.7±3.68min,是野生型的25倍,热稳定性显著提高。(2)本发明通过DNA合成改组组合突变方法,将前期所得到的正向突变随机组合,通过实验验证,该方法可有效地提高正突变概率,提高实验效率及可行性,并筛选得到热力学稳定性明显优于野生酶的突变酶。
附图说明
图1为ω-转氨酶依赖辅酶PLP可逆地催化氨基转移到前手性酮制备手性胺类化合物的催化过程示意图。
图2为DNA合成改组组合突变及固体平板筛选流程。
图3突变体的SDS-PAGE电泳分析结果图,其中,各泳道分别为M:protein marker;1:F115L-H210N-E253A-I295V,2:H210N-N245D-E253A-G292D,3:I77L-E133A-N245D-G292D,4:I77L-Q97E-F115L-L118T-E253A-G292D,5:I77L-F115L-E133A-H210N-N245D,6:F115L-H210N;7:F115L-H210N-M150C-M280C。
图4为实施例1中不同突变体酶和野生型酶的半衰期t1/2结果。
图5为实施例1中不同突变体酶和野生型酶的半失活温度T50 10结果。
图6为实施例1中差示荧光扫描法测定转氨酶及其突变酶的热解折叠结果Tm。
具体实施方式
实施例1
1、实验材料
(1)LB培养基:10g/L胰蛋白胨(购于Oxoid),5g/L酵母粉(购于Oxoid),10g/L氯化钠(购于生工生物工程有限公司(上海)),pH 7.0。LB固体培养基:LB液体培养基加入2%(质量比)琼脂粉。
氯化钠、甘油、氯化钙、咪唑、冰醋酸、磷酸氢二钠、磷酸二氢钠、5-磷酸吡哆醛、考马斯亮蓝蛋白质浓度测定试剂盒、Ni-NTA层析介质、异丙基-β-D-硫代半乳糖苷(IPTG)、硫酸卡那霉素、辣根过氧化物酶、氨苄青霉素、DNA和蛋白质Marker购于生工生物工程有限公司(上海)。本发明中经密码子优化的ω-转氨酶基因(ω-TA基因)委托通用生物系统(安徽)有限公司进行全基因合成,基因合成服务中使用pET-21a质粒作为克隆载体。
(2)二甲基亚砜(DMSO)、丙酮酸、(R)-(+)-α-甲基苄胺、3,3二氨基联苯胺四盐酸盐水合物(DAB)购自阿拉丁生化科技股份有限公司,PrimeSTAR Max DNA聚合酶购自TaKaRa公司;核算转移膜(印记膜)购于GE Healthcare公司,Dpn I购自Thermo Scientific公司。
(3)缓冲液配方:
20mmol/L洗脱缓冲液:50mmol/L磷酸二氢钠,300mmol/L氯化钠,20mmol/L咪唑,pH8.0;50mmol/L洗脱缓冲液:50mmol/L磷酸二氢钠,300mmol/L氯化钠,50mmol/L咪唑,pH8.0;100mmol/L洗脱缓冲液:50mmol/L磷酸二氢钠,300mmol/L氯化钠,100mmol/L咪唑,pH8.0;250mmol/L洗脱缓冲液:50mmol/L磷酸二氢钠,300mmol/L氯化钠,250mmol/L咪唑,pH8.0。
凝胶染色液:甲醇45.4mL,冰醋酸9.2mL,0.05g考马斯亮蓝R250,溶解于100mL去离子水;凝胶脱色液:甲醇5mL,冰醋酸7.5mL,溶解于100mL去离子水;电泳缓冲液:3.03gTris,14.4g甘氨酸,1g SDS,用去离子水定容至1L,0.22μm的滤纸抽滤后4℃冷藏。
2、组合突变
采用组合突变的方法,将前期筛选到的正向突变通过DNA合成改组被随机组合,以进一步提高转氨酶的热稳定性。用于创建组合基因库的寡核苷酸引物是基于Ness等所描述的方法,并通过利用简并密码子,以允许任何所需突变。其中,简并碱基S表示G/C,N表示A/T/C/G,R表示A/G,M表示A/C,K表示G/T,Y表示C/T。
表1组合突变引物及其序列
备注:下划线表示突变位点,引物名称中带有F的表示上游引物,带有R的表示下游引物。
突变文库及完整的目的基因片段如图2通过三步独立的PCR(两步组装PCR和一步放大PCR)完成,然后将PCR产物与pET-21a载体通过引物无缝克隆连接并转入大肠杆菌BL21(DE3)(含pRSF-DAAO质粒)感受态中。
(1)第一步PCR使用表1中的引物(F1-R12),每一组PCR使用四个相邻的寡核苷酸引物(两个正向和两个相反),PCR扩增体系:25μL PrimeSTAR Max Premix 2×;0.4μL内引物(10μM),2μL外引物(10μM),高温灭菌的超纯水补至总体积50μL。PCR扩增条件:98℃变性20s,55℃退火15s,72℃延伸30s,30个循环。取5μL PCR产物与loadingbuffer混匀后1%琼脂糖凝胶电泳分析检验后,将获得的11组不同的PCR产物分别取5μL混合并通过PCR产物纯化试剂盒进行纯化。
(2)第一步每一相邻两组PCR产物均有60bp左右重叠,第二部PCR则是将混合的各个片段进行组装成完整的目的基因。其50μL PCR扩增体系包含10μL纯化的PCR产物混合物,25μL PrimeSTAR Max Premix 2×和15μL高温灭菌的超纯水。PCR扩增条件:94℃变性30s,68℃延伸120s,20个循环。PCR产物经纯化试剂盒纯化。
(3)在经过第二部组装后,通过在线设计引物使其与目的基因和载体均有15~20bp左右重叠,并进一步设计引物在其蛋白质N端添加组氨酸标签。根据引物ATA-F,ATA-R进行第三步PCR,增加经过重新组装后的完整基因的数量。PCR扩增体系:25uL PrimeSTARMax Premix2×;2μL上游引物(10μM),2μL下游引物(10μM),1μL PCR产物模板(100ng/μL),高温灭菌的超纯水补至总体积50μL。PCR扩增条件:98℃变性1min;98℃变性20s,55℃退火15s,72℃延伸2min,共循环30次;72℃延伸7min。PCR产物经过电泳检测正确。
(4)pET-21a载体PCR:利用引物PET-21a-F,PET-21a-R进行载体PCR,使载体线性化并与目的基因存在15~20bp的同源臂。PCR扩增体系:25μL PrimeSTAR Max Premix 2×;2μL上游引物(10μM),2μL下游引物(10μM),1μL质粒模板(10ng/μL),高温灭菌的超纯水补至总体积50μL。PCR扩增条件:98℃变性1min;98℃变性20s,55℃退火15s,72℃延伸2min,共循环30次;72℃延伸7min。PCR产物经过电泳检测正确并通过胶回收试剂盒回收。所得胶回收产物采用Dpn I识别甲基化修饰的母本模板并将其降解。消化反应:PCR产物17μL,Buffer 2μL,Dpn I 1μL,37℃消化2h。
(5)同源重组:将目的基因与线性化载体连接。克隆载体使用量=[0.02×克隆载体碱基对数]ng(0.03pm),插入片段使用量=[0.04×克隆载体碱基对数]ng(0.03pm)。于冰上配制10μL重组反应体系:pET-21a线性化载体2μL(100ng/μL),目的基因片段2μL(40ng/μL),5μL ClonExpress Mix 2×,1μL ddH2O。重组条件:50℃连接30min,降至4度或立即置于冰上冷却。
将连接产物采用热击法转入E.coli BL 21感受态细胞(含pRSF-DAAO质粒)中。
3、含单质粒pRSF-DAAO大肠杆菌BL21(DE3)感受态的制备
(1)挑取新鲜的大肠杆菌单菌落于5mL LB液体培养基中,37℃下160r/min过夜培养至OD600为0.6-0.8左右。
(2)将2mL上述培养液按1%(v/v)的比例接入200mLLB液体培养基中,37℃、180r/min培养2h至OD600约为0.4左右。
(3)培养液冰水浴放置半小时,于4℃,4500r/min,离心10min收集菌体。
(4)用10mL预冷的10mM CaCl2重悬菌体细胞,置于冰水浴15min,于4℃,4500r/min,离心10min,收集菌体。
(5)重复步骤(4)。
(6)往菌体中加入6mL预冷的10mM CaCl2溶液(含15%甘油)。重悬菌体细胞,冰上放置3~5min,分装于无菌EP管中,保存于-80℃冰箱。
4、突变文库的建立
取出-80℃保藏的E.coli BL 21感受态细胞(含pRSF-DAAO质粒),冰上解冻后加入同源重组连接产物溶液(5~10μL),轻轻摇匀后置于冰上30min。42℃水浴中热击90s后,迅速置于冰上充分冷却3min。向管中加入0.8mLLB液体培养基,37℃培养1h,使细菌恢复正常生长状态,并表达双质粒编码的卡那霉素抗性和氨苄青霉素抗性基因。取100μL菌液均匀涂布于覆盖Hybond-N印记膜的LB平板上(含有50μg/mL的卡那霉素和100μg/mL的氨苄青霉素),正面向上放置0.5h,待菌液完全被培养基吸收后倒置平板,37℃培养16h。将膜印记于母板置于37℃继续生长12h后置于4度冰箱保存。然后将膜转移至含有0.2mm异丙基-β-D-硫代半乳糖苷(IPTG),50μg/mL的卡那霉素和100μg/mL的氨苄青霉素的LB平板上,置于25℃培养箱培养20h后将膜置于-80℃冰箱保存。
从上述平板上随机挑取单菌落接种至5mL含50μg/mL卡那霉素和100μg/mL的氨苄青霉素的LB培养基中,37℃、200r/min条件下培养3~4h。取1-2ul菌液稀释为100倍体积,沸水浴10-15mins进行菌液PCR验证双质粒的存在。以pET21a-ATA(Colony-F/R)和pRSF-DAAO(DAA0-F/R)质粒为模板设计引物菌落PCR体系如下:25μL PrimeSTAR Max Premix 2×;1μL上游引物(10μM),1μL下游引物(10μM),2μL模板,高温灭菌的超纯水补至总体积50μL。用1%的琼脂糖凝胶进行电泳检测。
5、突变文库的初筛与复筛
将含有马萝卜过氧化物酶(0.1mg/mL)、丙酮酸(0.2mg/mL)和50mMPBS(pH 8.0)的预筛选溶液预先浸泡在滤纸上。NC膜铺在滤纸上,室温下放置1h。将膜用液氮冻化,然后转移到预浸泡过的滤纸中,其中含有比色测定溶液:1x 3,3′-二氨基联苯胺片(麦克林),10mM底物,辣根过氧化物酶(0.1mg/mL),50mM PBS(pH 8.0)。将膜放在室温下,随着时间的推移,可以观察到颜色的变化。
用无菌牙签挑取出现颜色变化对应母板单菌落逐个接种于每孔含有1mL LB培养液(含卡那霉素50mg/mL和100mg/mL)96深孔板中,37℃,200r/min培养8h至指数生长后期。母板每孔移取200μL菌液于种子板相应孔,各孔加入100μL甘油(50%),混匀后菌种保存-80℃医用冰箱。母板中剩余的菌液每孔补充200μL LB培养液(含2.5mMIPTG),25℃,150r/min诱导20h,诱导结束后母板于4500r/min,离心10min,收集菌体。菌体用PBS(pH8.0)缓冲液清洗两遍,相同条件下离心,弃尽上清。将母板于超低温冰箱冷冻过夜后,取出母板室温解冻30min后,超低温冷冻20min,反复冻融三次。母板各孔中加入250μL溶菌酶(5mg/mL)重悬菌体,母板置于37℃,200r/min恒温孵育30min以充分裂解细胞释放胞内酶,然后离心10min(4500r/min)分离粗酶液和菌体。
每孔取80μL母板中的上清液(粗酶液)到96微量孔板的相应孔中,96微量孔板膜封后放入PCR仪中50℃恒温处理10min后,冰浴放置10min,粗酶液各20μL与180μL底物溶液混合,酶标仪检测粗酶液热处理前后催化转氨反应的酶活,定义相应酶未做热处理时候的酶活为100%。计算粗酶液热处理后的残余酶活百分比,选择残余酶活百分比高于野生型的突变子。最后选择残余酶活百分比位于TOP10的正向突变子,活化后送安徽通用生物公司测序分析。
6、突变体的表达与纯化
通过平板筛选了大约3000个菌落之后获得了一些残余活力较高的正向突变,将E.coli BL 21感受态细胞与测序正确的转氨酶突变体质粒置于冰水浴5min,取10μL质粒加到感受态细胞,轻轻混匀,冰上放置30min,42℃水浴锅热击90s,迅速放回冰浴中3min,加入600μL LB培养基,于37℃、180r/min复苏50min。150μL培养液均匀涂布于LB固体平板(含卡那霉素50μg/mL和氨苄青霉素100μg/mL),37℃培养箱培养30min,再倒置平板过夜培养。
挑取单菌落接种至加有5mLLB液体培养基的试管中,37℃、200r/min条件下培养过夜。将培养好的菌液以1%比例(体积比)的接种量接种至含50μg/mL卡那霉素和100μg/mL氨苄青霉素的200mL LB培养基中,37℃、180r/min培养至OD600值为0.4~0.6时,加入适量体积的IPTG(终浓度为1mmol/L),然后在16~30℃、150~200r/min条件下诱导培养18h后,收集菌体。
将收集的菌体用磷酸盐缓冲液洗涤两次,悬浮于50mL破胞缓冲液(50mM磷酸二氢钠,300mM氯化钠,20mM咪唑,pH 8.0)中。冰浴条件下对菌体细胞进行均质机破碎细胞。破胞液于12000r/min、4℃条件下离心处理30min,收集上清液,即得到含有的ω-转氨酶粗酶液。
采用Ni-NTA亲和层析对所得的粗酶液进行分离纯化。经上样、清洗和洗脱,收集洗脱液,透析除去小分子即得到纯酶。适当稀释后,以考马斯亮蓝法测定纯酶的浓度。具体纯化步骤:
(1)平衡Ni-NTA亲和层析柱:20%乙醇,去离子水和20mM咪唑缓冲液各3柱体积;
(2)上样:注射器吸取粗酶液经0.45μm滤膜过滤,带有6个组氨酸标签的重组蛋白与填料特异性结合;
(3)清洗:50mM咪唑缓冲液2-3柱体积,Bradford溶液检测是否除尽杂蛋白;
(4)洗脱:100mM洗脱缓冲液5mL,250mM洗脱缓冲液5mL;
(5)保存柱子:20mM咪唑缓冲液,去离子水和20%乙醇各3柱体积,最后保存于20%乙醇中。
7、转氨酶突变体的SDS-PAGE分析
采用改良型Bradford蛋白浓度测定试剂盒建立蛋白含量标准曲线,测定纯酶的浓度,蛋白标准曲线的制备步骤参照说明书进行。采用SDS-PAGE方法(12%分离胶和5%浓缩胶)鉴定纯化后蛋白的分子量和纯度。
样品处理:粗酶液40μL与5×蛋白加样缓冲液10μL混匀,沸水浴10min。
上样:蛋白Marker 5μL,样品10μL。
电泳条件:电压170V,电泳约45min,待溴酚蓝指示剂移至距凝胶下端边缘约1cm处停止电泳。
染色:染色液没过凝胶,微波炉加热1min,于摇床染色25min。
脱色:回收染色液,换上脱色液,每小时换一次脱色液,至蛋白条带清晰。
转氨酶突变体L118T的SDS-PAGE分析如图3,蛋白分子量接近于野生型酶理论分子量36.1kDa。
8、突变酶的浓缩
转氨酶的分子量大约是36.1kDa,一般截留分子量为目的蛋白分子量的1/5~1/3之间,选择截留分子量为10kDa的浓缩管。
浓缩管的预处理:依次用20%乙醇、去离子水和PBS缓冲液(pH 8.0),于4℃,4000r/min,离心10min。
酶的浓缩:往浓缩管加入5mL待浓缩的酶,于4℃,4000r/min,离心15-20min至酶液体积约1mL。然后加入多倍体积的PBS缓冲液(pH 8.0),于4℃,4000r/min,离心20min,重复两次。取出内管浓缩的酶液,低温保存。
浓缩管的后处理:依次用PBS缓冲液、去离子水和20%乙醇,在4℃,4000r/min,离心10min,最后往内管中加20%乙醇没过膜上端,保存于4℃冰箱。
9、突变酶活力的测定
以(R)-(+)-α-甲基苄胺和丙酮酸为底物,底物溶液用磷酸盐缓冲液(50mM,pH8.0)配制,200μL的反应体系中包括180μL底物溶(0.25%DMSO,2.5mM(R)-(+)-α-甲基苄胺,2.5mM丙酮酸,0.1mM PLP),20μL纯酶液(约0.3mg/mL)。利用酶标仪检测波长245nm处OD值随时间的变化曲线。酶活计算方法如下公式1:
其中,ΔOD245:在245nm处每分钟吸光度的变化;V:酶反应体系总体积(200μL);d:光径(0.6cm);ε:为苯乙酮的摩尔吸光系数(12000L/(mol·cm));VE:反应体系中酶的体积(20μL);[E]:酶的浓度(mg/mL)。结果如表2所示。
表2野生型和突变体的动力学参数
10、突变酶热稳定性参数的测定
分别将纯化后的野生酶和突变酶在25-55℃水浴中孵育10min,随后迅速放置在冰上冷却10min。底物溶液用磷酸盐缓冲液(50mmol/L,pH 8.0)配制,200μL的反应体系中包括180μL的底物溶液(0.25%DMSO、2.5mmol/L(R)-(+)-α-甲基苄胺((R)-α-MBA)、2.5mmol/L丙酮酸以及0.1mmol/L PLP),20μL纯酶液(约0.3mg/mL),采用MD190酶标仪检测波长在245nm处相应的酶活力(Purmonen M,Valjakka J,Takkinen K,et al.Molecular dynamicsstudies on the thermostability of family 11xylanases[J].Protein EngineeringDesign and Selection,2007,20(11):551-559.)。
以温度为横坐标,以热处理后与处理前酶活力的比值为纵坐标作图,采用Origin8.0软件进行Boltzmann S型函数拟合,计算半失活温度(T50 10)。
将野生酶和突变酶在40℃下分别孵育2-50min,孵育结束后迅速放置在冰上冷却10min,采用上述方法测定酶活力。以时间为横坐标,以热处理后与处理前的比活力的比值为纵坐标作图,通过Origin 8.0软件拟合非线性方程y=exp(-kd·t),一阶速率常数(kd)经非线性回归确定,并计算酶活力降低为50%时所对应的半衰期(t1/2)。
实验结果如表3和图4、图5所示。
11、突变酶热力学稳定性表征
差示扫描荧光测定法(DSF)是一种快速、低成本的研究蛋白质稳定性及蛋白质与小分子作用的方法。适当稀释待分析纯酶(浓缩除咪唑)(0.1mg/mL)与荧光染料SYPROOrange dye 2×,50mM PBS缓冲液(pH 8.0)和150mM NaCl混合,总体积50μL,以酶缓冲液为阴性对照,每个样品平行测定三组。装有待分析样品的PCR管放入实时荧光定量PCR仪中进行程序升温,温度上升速率为0.7℃/30s。实时荧光定量PCR仪记录酶样品在25℃升至70℃条件下的荧光强度变化。其中激发波长为490nm,发射波长为605nm。以荧光强度对温度作图,曲线呈S型,其中曲线的拐点即为蛋白质的热解折叠温度(Tm)。
酶的热动力学分析采用二态平衡模型,Tm值根据Boltzmann公式2计算获得:
其中,y代表不同温度下的荧光强度,UF是酶天然折叠状态的荧光强度,NF为解折叠状态下最大荧光强度,x指温度,dx是荧光强度与温度关系曲线的斜率。使用软件Origin8.0进行拟合,求得Tm。
表3野生型和突变体的稳定性参数
名称 | T<sub>50</sub><sup>15</sup>(℃) | t<sub>1/2</sub>(min) | T<sub>m</sub> |
WT-ATA | 38.50±0.5 | 6.90±0.6 | 41.4±0.2 |
F115L-H210N-M150C-M280C | 52.20±0.42 | 172.7±3.68 | 55.3±0.29 |
F115L-H210N | 49.78±0.5 | 101.2±0.13 | 54.3±0.25 |
F115L-H210N-E253A-I295V | 47.86±0.28 | 65.54±1 | 50.0±0.34 |
I77L-F115L-E133A-H210N-N245D | 47.65±0.22 | 60.8±0.7 | 53.8±0.28 |
I77L-Q97E-F115L-L118T-E253A-G292D | 45.62±0.44 | 41.68±0.9 | 49.9±0.13 |
I77L-E133A-N245D-G292D | 44.81±0.45 | 37.4±2.4 | 48.7±0.34 |
H210N-N245D-E253A-G292D | 41.8±0.53 | 12.55±0.48 | 44.3±0.33 |
实验结果如表3,图6所示。
序列表
<110> 浙江科技学院
宁波酶赛生物工程有限公司
<120> 一种通过DNA合成改组组合突变获得的ω-转氨酶突变体及应用
<160> 41
<170> SIPOSequenceListing 1.0
<210> 1
<211> 325
<212> PRT
<213> 土曲霉(Aspergillus terreus)
<400> 1
Met Ala Ser Met Asp Lys Val Phe Ala Gly Tyr Ala Ala Arg Gln Ala
1 5 10 15
Ile Leu Glu Ser Thr Glu Thr Thr Asn Pro Phe Ala Lys Gly Ile Ala
20 25 30
Trp Val Glu Gly Glu Leu Val Pro Leu Ala Glu Ala Arg Ile Pro Leu
35 40 45
Leu Asp Gln Gly Phe Met His Ser Asp Leu Thr Tyr Asp Val Pro Ser
50 55 60
Val Trp Asp Gly Arg Phe Phe Arg Leu Asp Asp His Ile Thr Arg Leu
65 70 75 80
Glu Ala Ser Cys Thr Lys Leu Arg Leu Arg Leu Pro Leu Pro Arg Asp
85 90 95
Gln Val Lys Gln Ile Leu Val Glu Met Val Ala Lys Ser Gly Ile Arg
100 105 110
Asp Ala Phe Val Glu Leu Ile Val Thr Arg Gly Leu Lys Gly Val Arg
115 120 125
Gly Thr Arg Pro Glu Asp Ile Val Asn Asn Leu Tyr Met Phe Val Gln
130 135 140
Pro Tyr Val Trp Val Met Glu Pro Asp Met Gln Arg Val Gly Gly Ser
145 150 155 160
Ala Val Val Ala Arg Thr Val Arg Arg Val Pro Pro Gly Ala Ile Asp
165 170 175
Pro Thr Val Lys Asn Leu Gln Trp Gly Asp Leu Val Arg Gly Met Phe
180 185 190
Glu Ala Ala Asp Arg Gly Ala Thr Tyr Pro Phe Leu Thr Asp Gly Asp
195 200 205
Ala His Leu Thr Glu Gly Ser Gly Phe Asn Ile Val Leu Val Lys Asp
210 215 220
Gly Val Leu Tyr Thr Pro Asp Arg Gly Val Leu Gln Gly Val Thr Arg
225 230 235 240
Lys Ser Val Ile Asn Ala Ala Glu Ala Phe Gly Ile Glu Val Arg Val
245 250 255
Glu Phe Val Pro Val Glu Leu Ala Tyr Arg Cys Asp Glu Ile Phe Met
260 265 270
Cys Thr Thr Ala Gly Gly Ile Met Pro Ile Thr Thr Leu Asp Gly Met
275 280 285
Pro Val Asn Gly Gly Gln Ile Gly Pro Ile Thr Lys Lys Ile Trp Asp
290 295 300
Gly Tyr Trp Ala Met His Tyr Asp Ala Ala Tyr Ser Phe Glu Ile Asp
305 310 315 320
Tyr Asn Glu Arg Asn
325
<210> 2
<211> 978
<212> DNA
<213> 土曲霉(Aspergillus terreus)
<400> 2
atggccagta tggataaggt ttttgcaggc tatgctgccc gtcaagcaat cttagaaagt 60
accgaaacta cgaacccgtt tgccaaagga attgcctggg tcgaagggga actcgttcct 120
ttagctgaag cacgcattcc actcctcgat cagggcttca tgcactccga tctgacctac 180
gacgtaccgt ctgtttggga tgggcgattt tttcgtttag atgatcatat tacacgcctg 240
gaagcaagct gcaccaagct gaggctgcgt ctacccttac cacgtgatca agttaaacaa 300
atcctggtgg aaatggtcgc aaaatctggt attcgggatg catttgttga attgatagtc 360
acccgcggtc ttaaaggggt gcgaggaact cgtccgcatg atatagtgaa caacctgtac 420
atgtttgtgc agccgtacgt gtgggttatg gagccggata tgcagcgcgt aggcggcagc 480
gcagtggtgg ctaggaccgt ccgccgggta ccaccgggcg ctattgatcc gaccgtcaag 540
aatcttcagt ggggtgatct tgttcgtgga atgtttgaag cggctgatcg tggcgcaaca 600
tatcccttcc ttaccgacgg cgatgcgcac ctgactgaag gatcgggttt taatatagta 660
ttagtcaaag atggcgtcct gtatacgcca gatcgcgggg tgctgcaggg agtgactcgc 720
aagtccgtta tcaacgctgc tgaagccttt ggaatagaag tgcgggttga gttcgttcca 780
gttgagctgg cctaccggtg tgacgagatt ttcatgtgca cgacggcggg tggcattatg 840
cctatcacaa cattggacgg tatgcctgta aatggtgggc aaattgggcc tattacgaaa 900
aaaatatggg acggttattg ggcgatgcat tatgacgccg cgtattcgtt cgagatcgac 960
tataatgaga gaaattag 978
<210> 3
<211> 978
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 3
atggccagta tggataaggt ttttgcaggc tatgctgccc gtcaagcaat cttagaaagt 60
accgaaacta cgaacccgtt tgccaaagga attgcctggg tcgaagggga actcgttcct 120
ttagctgaag cacgcattcc actcctcgat cagggcttca tgcactccga tctgacctac 180
gacgtaccgt ctgtttggga tgggcgattt tttcgtttag atgatcatat tacacgcctg 240
gaagcaagct gcaccaagct gaggctgcgt ctacccttac cacgtgatca agttaaacaa 300
atcctggtgg aaatggtcgc aaaatctggt attcgggatg cattagttga attgatagtc 360
acccgcggtc ttaaaggggt gcgaggaact cgtccggaag atatagtgaa caacctgtac 420
atgtttgtgc agccgtacgt gtgggtttgc gagccggata tgcagcgcgt aggcggcagc 480
gcagtggtgg ctaggaccgt ccgccgggta ccaccgggcg ctattgatcc gaccgtcaag 540
aatcttcagt ggggtgatct tgttcgtgga atgtttgaag cggctgatcg tggcgcaaca 600
tatcccttcc ttaccgacgg cgatgcgaac ctgactgaag gatcgggttt taatatagta 660
ttagtcaaag atggcgtcct gtatacgcca gatcgcgggg tgctgcaggg agtgactcgc 720
aagtccgtta tcaacgctgc tgaagccttt ggaatagcgg tgcgggttga gttcgttcca 780
gttgagctgg cctaccggtg tgacgagatt ttcatgtgca cgacggcggg tggcatttgc 840
cctatcacaa cattggacgg tatgcctgta aatggtgggc aaattgggcc tattacgaaa 900
aaaatatggg acggttattg ggcgatgcat tatgacgccg cgtattcgtt cgagatcgac 960
tataatgaga gaaattag 978
<210> 4
<211> 978
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 4
atggccagta tggataaggt ttttgcaggc tatgctgccc gtcaagcaat cttagaaagt 60
accgaaacta cgaacccgtt tgccaaagga attgcctggg tcgaagggga actcgttcct 120
ttagctgaag cacgcattcc actcctcgat cagggcttca tgcactccga tctgacctac 180
gacgtaccgt ctgtttggga tgggcgattt tttcgtttag atgatcatat tacacgcctg 240
gaagcaagct gcaccaagct gaggctgcgt ctacccttac cacgtgatca agttaaacaa 300
atcctggtgg aaatggtcgc aaaatctggt attcgggatg cattagttga attgatagtc 360
acccgcggtc ttaaaggggt gcgaggaact cgtccggaag atatagtgaa caacctgtac 420
atgtttgtgc agccgtacgt gtgggttatg gagccggata tgcagcgcgt aggcggcagc 480
gcagtggtgg ctaggaccgt ccgccgggta ccaccgggcg ctattgatcc gaccgtcaag 540
aatcttcagt ggggtgatct tgttcgtgga atgtttgaag cggctgatcg tggcgcaaca 600
tatcccttcc ttaccgacgg cgatgcgaac ctgactgaag gatcgggttt taatatagta 660
ttagtcaaag atggcgtcct gtatacgcca gctcgcgggg tgctgcaggg agtgactcgc 720
aagtccgtta tcaacgctgc tgaagccttt ggaatagaag tgcgggttga gttcgttcca 780
gttgagctgg cctaccggtg tgacgagatt ttcatgtgca cgacggcggg tggcattatg 840
cctatcacaa cattggacgg tatgcctgta aatggtgggc aaattgggcc tattacgaaa 900
aaaatatggg acggttattg ggcgatgcat tatgacgccg cgtattcgtt cgagatcgac 960
tataatgaga gaaattag 978
<210> 5
<211> 978
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 5
atggccagta tggataaggt ttttgcaggc tatgctgccc gtcaagcaat cttagaaagt 60
accgaaacta cgaacccgtt tgccaaagga attgcctggg tcgaagggga actcgttcct 120
ttagctgaag cacgcattcc actcctcgat cagggcttca tgcactccga tctgacctac 180
gacgtaccgt ctgtttggga tgggcgattt tttcgtttag atgatcatat tacacgcctg 240
gaagcaagct gcaccaagct gaggctgcgt ctacccttac cacgtgatca agttaaacaa 300
atcctggtgg aaatggtcgc aaaatctggt attcgggatg cattagttga attgatagtc 360
acccgcggtc ttaaaggggt gcgaggaact cgtccgcaag atatagtgaa caacctgtac 420
atgtttgtgc agccgtacgt gtgggttatg gagccggata tgcagcgcgt aggcggcagc 480
gcagtggtgg ctaggaccgt ccgccgggta ccaccgggcg ctattgatcc gaccgtcaag 540
aatcttcagt ggggtgatct tgttcgtgga atgtttgaag cggctgatcg tggcgcaaca 600
tatcccttcc ttaccgacgg cgatgcgcaa ctgactgaag gatcgggttt taatatagta 660
ttagtcaaag atggcgtcct gtatacgcca gatcgcgggg tgctgcaggg agtgactcgc 720
aagtccgtta tcaacgctgc tgaagccttt ggaatagcag tgcgggttga gttcgttcca 780
gttgagctgg cctaccggtg tgacgagatt ttcatgtgca cgacggcggg tggcattatg 840
cctatcacaa cattggacgg tatgcctgta aatggtgggc aagttgggcc tattacgaaa 900
aaaatatggg acggttattg ggcgatgcat tatgacgccg cgtattcgtt cgagatcgac 960
tataatgaga gaaattag 978
<210> 6
<211> 978
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 6
atggccagta tggataaggt ttttgcaggc tatgctgccc gtcaagcaat cttagaaagt 60
accgaaacta cgaacccgtt tgccaaagga attgcctggg tcgaagggga actcgttcct 120
ttagctgaag cacgcattcc actcctcgat cagggcttca tgcactccga tctgacctac 180
gacgtaccgt ctgtttggga tgggcgattt tttcgtttag atgatcatct tacacgcctg 240
gaagcaagct gcaccaagct gaggctgcgt ctacccttac cacgtgatca agttaaacaa 300
atcctggtgg aaatggtcgc aaaatctggt attcgggatg cattagttga attgatagtc 360
acccgcggtc ttaaaggggt gcgaggaact cgtccggcag atatagtgaa caacctgtac 420
atgtttgtgc agccgtacgt gtgggttatg gagccggata tgcagcgcgt aggcggcagc 480
gcagtggtgg ctaggaccgt ccgccgggta ccaccgggcg ctattgatcc gaccgtcaag 540
aatcttcagt ggggtgatct tgttcgtgga atgtttgaag cggctgatcg tggcgcaaca 600
tatcccttcc ttaccgacgg cgatgcgaac ctgactgaag gatcgggttt taatatagta 660
ttagtcaaaa aaggcgtcct gtatacgcca gatcgcgggg tgctgcaggg agtgactcgc 720
aagtccgtta tcgacgctgc tgaagccttt ggaatagaag tgcgggttga gttcgttcca 780
gttgagctgg cctaccggtg tgacgagatt ttcatgtgca cgacggcggg tggcattatg 840
cctatcacaa cattggacgg tatgcctgta aatggtgggc aaattgggcc tattacgaaa 900
aaaatatggg acggttattg ggcgatgcat tatgacgccg cgtattcgtt cgagatcgac 960
tataatgaga gaaattag 978
<210> 7
<211> 978
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 7
atggccagta tggataaggt ttttgcaggc tatgctgccc gtcaagcaat cttagaaagt 60
accgaaacta cgaacccgtt tgccaaagga attgcctggg tcgaagggga actcgttcct 120
ttagctgaag cacgcattcc actcctcgat cagggcttca tgcactccga tctgacctac 180
gacgtaccgt ctgtttggga tgggcgattt tttcgtttag atgatcatct tacacgcctg 240
gaagcaagct gcaccaagct gaggctgcgt ctacccttac cacgtgatga agttaaacaa 300
atcctggtgg aaatggtcgc aaaatctggt attcgggatg cattagttga aacgatagtc 360
acccgcggtc ttaaaggggt gcgaggaact cgtccggaag atatagtgaa caacctgtac 420
atgtttgtgc agccgtacgt gtgggttatg gagccggata tgcagcgcgt aggcggcagc 480
gcagtggtgg ctaggaccgt ccgccgggta ccaccgggcg ctattgatcc gaccgtcaag 540
aatcttcagt ggggtgatct tgttcgtgga atgtttgaag cggctgatcg tggcgcaaca 600
tatcccttcc ttaccgacgg cgatgcgcac ctgactgaag gatcgggttt taatatagta 660
ttagtcaaag ctggcgtcct gtatacgcca gatcgcgggg tgctgcaggg agtgactcgc 720
aagtccgtta tcaacgctgc tgaagccttt ggaatagcag tgcgggttga gttcgttcca 780
gttgagctgg cctaccggtg tgacgagatt ttcatgtgca cgacggcggg tggcattatg 840
cctatcacaa cattggacgg tatgcctgta aatgatgggc aaattgggcc tattacgaaa 900
aaaatatggg acggttattg ggcgatgcat tatgacgccg cgtattcgtt cgagatcgac 960
tataatgaga gaaattag 978
<210> 8
<211> 978
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 8
atggccagta tggataaggt ttttgcaggc tatgctgccc gtcaagcaat cttagaaagt 60
accgaaacta cgaacccgtt tgccaaagga attgcctggg tcgaagggga actcgttcct 120
ttagctgaag cacgcattcc actcctcgat cagggcttca tgcactccga tctgacctac 180
gacgtaccgt ctgtttggga tgggcgattt tttcgtttag atgatcatct tacacgcctg 240
gaagcaagct gcaccaagct gaggctgcgt ctacccttac cacgtgatca agttaaacaa 300
atcctggtgg aaatggtcgc aaaatctggt attcgggatg catttgttga attgatagtc 360
acccgcggtc ttaaaggggt gcgaggaact cgtccggcag atatagtgaa caacctgtac 420
atgtttgtgc agccgtacgt gtgggttatg gagccggata tgcagcgcgt aggcggcagc 480
gcagtggtgg ctaggaccgt ccgccgggta ccaccgggcg ctattgatcc gaccgtcaag 540
aatcttcagt ggggtgatct tgttcgtgga atgtttgaag cggctgatcg tggcgcaaca 600
tatcccttcc ttaccgacgg cgatgcgcac ctgactgaag gatcgggttt taatatagta 660
ttagtcaaag atggcgtcct gtatacgcca gatcgcgggg tgctgcaggg agtgactcgc 720
aagtccgtta tcgacgctgc tgaagccttt ggaatagaag tgcgggttga gttcgttcca 780
gttgagctgg cctaccggtg tgacgagatt ttcatgtgca cgacggcggg tggcattatg 840
cctatcacaa cattggacgg tatgcctgta aatgatgggc aaattgggcc tattacgaaa 900
aaaatatggg acggttattg ggcgatgcat tatgacgccg cgtattcgtt cgagatcgac 960
tataatgaga gaaattag 978
<210> 9
<211> 978
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 9
atggccagta tggataaggt ttttgcaggc tatgctgccc gtcaagcaat cttagaaagt 60
accgaaacta cgaacccgtt tgccaaagga attgcctggg tcgaagggga actcgttcct 120
ttagctgaag cacgcattcc actcctcgat cagggcttca tgcactccga tctgacctac 180
gacgtaccgt ctgtttggga tgggcgattt tttcgtttag atgatcatat tacacgcctg 240
gaagcaagct gcaccaagct gaggctgcgt ctacccttac cacgtgatca agttaaacaa 300
atcctggtgg aaatggtcgc aaaatctggt attcgggatg catttgttga attgatagtc 360
acccgcggtc ttaaaggggt gcgaggaact cgtccgcgtg atatagtgaa caacctgtac 420
atgtttgtgc agccgtacgt gtgggttatg gagccggata tgcagcgcgt aggcggcagc 480
gcagtggtgg ctaggaccgt ccgccgggta ccaccgggcg ctattgatcc gaccgtcaag 540
aatcttcagt ggggtgatct tgttcgtgga atgtttgaag cggctgatcg tggcgcaaca 600
tatcccttcc ttaccgacgg cgatgcgaac ctgactgaag gatcgggttt taatatagta 660
ttagtcaaag atggcgtcct gtatacgcca gatcgcgggg tgctgcaggg agtgactcgc 720
aagtccgtta tcgacgctgc tgaagccttt ggaatagaag tgcgggttga gttcgttcca 780
gttgagctgg cctaccggtg tgacgagatt ttcatgtgca cgacggcggg tggcattatg 840
cctatcacaa cattggacgg tatgcctgta aatgatgggc aaattgggcc tattacgaaa 900
aaaatatggg acggttattg ggcgatgcat tatgacgccg cgtattcgtt cgagatcgac 960
tataatgaga gaaattag 978
<210> 10
<211> 51
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 10
atggccagta tggataaggt ttttgcaggc tatgctgccc gtcaagcaat c 51
<210> 11
<211> 60
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 11
cccgtttgcc aaaggaattg cctgggtcga aggggaactc gttcctttag ctgaagcacg 60
<210> 12
<211> 60
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 12
gcttcatgca ctccgatctg acctacgacg taccgtctgt ttgggatggg cgattttttc 60
<210> 13
<211> 60
<212> DNA
<213> 人工序列(Artificial Sequence)
<220>
<221> variation
<222> (51)..(51)
<223> s stands for g/c.
<400> 13
tggaagcaag ctgcaccaag ctgaggctgc gtctaccctt accacgtgat saagttaaac 60
<210> 14
<211> 60
<212> DNA
<213> 人工序列(Artificial Sequence)
<220>
<221> variation
<222> (23)..(23)
<223> n stands for a/t/c/g.
<220>
<221> misc_feature
<222> (23)..(23)
<223> n is a, c, g, t or u
<400> 14
aatctggtat tcgggatgca ttngttgaat tgatagtcac ccgcggtctt aaaggggtgc 60
<210> 15
<211> 60
<212> DNA
<213> 人工序列(Artificial Sequence)
<220>
<221> variation
<222> (23)..(23)
<223> n stands for a/t/c/g.
<220>
<221> misc_feature
<222> (23)..(23)
<223> n is a, c, g, t or u
<400> 15
aatctggtat tcgggatgca ttngttgaaa cgatagtcac ccgcggtctt aaaggggtgc 60
<210> 16
<211> 60
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 16
tagtgaacaa cctgtacatg tttgtgcagc cgtacgtgtg ggttatggag ccggatatgc 60
<210> 17
<211> 60
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 17
tagtgaacaa cctgtacatg tttgtgcagc cgtacgtgtg ggtttgcgag ccggatatgc 60
<210> 18
<211> 60
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 18
tggtggctag gaccgtccgc cgggtaccac cgggcgctat tgatccgacc gtcaagaatc 60
<210> 19
<211> 60
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 19
tgttcgtgga atgtttgaag cggctgatcg tggcgcaaca tatcccttcc ttaccgacgg 60
<210> 20
<211> 60
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 20
gatcgggttt taatatagta ttagtcaaag atggcgtcct gtatacgcca gatcgcgggg 60
<210> 21
<211> 60
<212> DNA
<213> 人工序列(Artificial Sequence)
<220>
<221> variation
<222> (12)..(12)
<223> r stands for a/g.
<220>
<221> variation
<222> (37)..(37)
<223> m stands for a/c.
<400> 21
agtccgttat cracgctgct gaagcctttg gaatagmagt gcgggttgag ttcgttccag 60
<210> 22
<211> 60
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 22
tgacgagatt ttcatgtgca cgacggcggg tggcattatg cctatcacaa cattggacgg 60
<210> 23
<211> 60
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 23
tgacgagatt ttcatgtgca cgacggcggg tggcatttgc cctatcacaa cattggacgg 60
<210> 24
<211> 60
<212> DNA
<213> 人工序列(Artificial Sequence)
<220>
<221> variation
<222> (3)..(3)
<223> r stands for a/g.
<400> 24
aarttgggcc tattacgaaa aaaatatggg acggttattg ggcgatgcat tatgacgccg 60
<210> 25
<211> 60
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 25
caattccttt ggcaaacggg ttcgtagttt cggtactttc taagattgct tgacgggcag 60
<210> 26
<211> 60
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 26
cagatcggag tgcatgaagc cctgatcgag gagtggaatg cgtgcttcag ctaaaggaac 60
<210> 27
<211> 60
<212> DNA
<213> 人工序列(Artificial Sequence)
<220>
<221> variation
<222> (26)..(26)
<223> k stands for g/t.
<400> 27
gtgcagcttg cttccaggcg tgtaakatga tcatctaaac gaaaaaatcg cccatcccaa 60
<210> 28
<211> 60
<212> DNA
<213> 人工序列(Artificial Sequence)
<220>
<221> variation
<222> (52)..(52)
<223> s stands for g/c.
<400> 28
catcccgaat accagatttt gcgaccattt ccaccaggat ttgtttaact tsatcacgtg 60
<210> 29
<211> 60
<212> DNA
<213> 人工序列(Artificial Sequence)
<220>
<221> variation
<222> (26)..(26)
<223> k stands for g/t.
<400> 29
catgtacagg ttgttcacta tatctkccgg acgagttcct cgcacccctt taagaccgcg 60
<210> 30
<211> 60
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 30
gcggacggtc ctagccacca ctgcgctgcc gcctacgcgc tgcatatccg gctccataac 60
<210> 31
<211> 60
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 31
gcggacggtc ctagccacca ctgcgctgcc gcctacgcgc tgcatatccg gctcgcaaac 60
<210> 32
<211> 60
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 32
cttcaaacat tccacgaaca agatcacccc actgaagatt cttgacggtc ggatcaatag 60
<210> 33
<211> 60
<212> DNA
<213> 人工序列(Artificial Sequence)
<220>
<221> variation
<222> (33)..(33)
<223> k stands for g/t.
<400> 33
tactatatta aaacccgatc cttcagtcag gtkcgcatcg ccgtcggtaa ggaagggata 60
<210> 34
<211> 60
<212> DNA
<213> 人工序列(Artificial Sequence)
<220>
<221> variation
<222> (8)..(8)
<223> y stands for c/t.
<400> 34
gcagcgtyga taacggactt gcgagtcact ccctgcagca ccccgcgatc tggcgtatac 60
<210> 35
<211> 60
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 35
gcacatgaaa atctcgtcac accggtaggc cagctcaact ggaacgaact caacccgcac 60
<210> 36
<211> 60
<212> DNA
<213> 人工序列(Artificial Sequence)
<220>
<221> variation
<222> (18)..(18)
<223> y stands for c/t.
<220>
<221> variation
<222> (26)..(26)
<223> y stands for c/t.
<400> 36
tttcgtaata ggcccaaytt gcccaycatt tacaggcata ccgtccaatg ttgtgatagg 60
<210> 37
<211> 51
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 37
ctaatttctc tcattatagt cgatctcgaa cgaatacgcg gcgtcataat g 51
<210> 38
<211> 66
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 38
ggctagcatg actggtggac atgcaccacc accaccacca catggccagt atggataagg 60
tttttg 66
<210> 39
<211> 51
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 39
gagtgcggcc gcaagcttgt ctaatttctc tcattatagt cgatctcgaa c 51
<210> 40
<211> 18
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 40
acaagcttgc ggccgcac 18
<210> 41
<211> 25
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 41
gtccaccagt catgctagcc atatg 25
Claims (8)
1.一种通过DNA合成改组组合突变获得的ω-转氨酶突变体,其特征在于,由来自土曲霉(Aspergillus terreus)的野生型ω-转氨酶进行点突变而得,野生型ω-转氨酶的氨基酸序列如SEQ ID No.1所示,所述ω-转氨酶突变体的突变位点为:F115L-H210N。
2.如权利要求1所述的ω-转氨酶突变体在催化(R)-(+)-α-甲基苄胺生成苯乙酮中的应用。
3.编码如权利要求1所述ω-转氨酶突变体的基因。
4.如权利要求3所述的基因,其特征在于,核苷酸序列如SEQ ID No.4。
5.如权利要求3所述基因在催化(R)-(+)-α-甲基苄胺生成苯乙酮中的应用。
6.包含如权利要求3所述基因的重组表达载体。
7.包含如权利要求6所述重组表达质粒的基因工程菌。
8.如权利要求7所述基因工程菌在催化(R)-(+)-α-甲基苄胺生成苯乙酮中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111345072.6A CN114181918B (zh) | 2020-12-04 | 2020-12-04 | 一种通过DNA合成改组组合突变获得的ω-转氨酶突变体及应用 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111345072.6A CN114181918B (zh) | 2020-12-04 | 2020-12-04 | 一种通过DNA合成改组组合突变获得的ω-转氨酶突变体及应用 |
CN202011415007.1A CN112481230B (zh) | 2020-12-04 | 2020-12-04 | 一种通过DNA合成改组组合突变获得的ω-转氨酶突变体及应用 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011415007.1A Division CN112481230B (zh) | 2020-12-04 | 2020-12-04 | 一种通过DNA合成改组组合突变获得的ω-转氨酶突变体及应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114181918A true CN114181918A (zh) | 2022-03-15 |
CN114181918B CN114181918B (zh) | 2023-09-15 |
Family
ID=74940257
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011415007.1A Active CN112481230B (zh) | 2020-12-04 | 2020-12-04 | 一种通过DNA合成改组组合突变获得的ω-转氨酶突变体及应用 |
CN202111331763.0A Active CN114107241B (zh) | 2020-12-04 | 2020-12-04 | 一种通过DNA合成改组组合突变获得的ω-转氨酶突变体及应用 |
CN202111345072.6A Active CN114181918B (zh) | 2020-12-04 | 2020-12-04 | 一种通过DNA合成改组组合突变获得的ω-转氨酶突变体及应用 |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011415007.1A Active CN112481230B (zh) | 2020-12-04 | 2020-12-04 | 一种通过DNA合成改组组合突变获得的ω-转氨酶突变体及应用 |
CN202111331763.0A Active CN114107241B (zh) | 2020-12-04 | 2020-12-04 | 一种通过DNA合成改组组合突变获得的ω-转氨酶突变体及应用 |
Country Status (2)
Country | Link |
---|---|
US (1) | US20220177933A1 (zh) |
CN (3) | CN112481230B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117126824A (zh) * | 2022-05-18 | 2023-11-28 | 江苏美科生物科技有限公司 | 一种转氨酶的突变体及其在制备西他列汀中间体生产中的应用 |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113284562B (zh) * | 2021-06-07 | 2021-12-24 | 中国农业科学院农业基因组研究所 | 一种酶的改良方法 |
CN114134128B (zh) * | 2021-12-07 | 2023-05-23 | 浙江科技学院 | 一种基于祖先序列重建的ω-转氨酶突变体 |
CN114645030B (zh) * | 2022-04-08 | 2023-11-17 | 浙江科技学院 | 一种ω-转氨酶突变体及其在制备西塞卡纳药物中间体的应用 |
CN116254253B (zh) * | 2022-11-11 | 2024-06-28 | 浙大宁波理工学院 | 一种通过dna合成改组组合突变获得的谷氨酸脱羧酶突变体及应用 |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002253272A (ja) * | 2000-08-17 | 2002-09-10 | Ajinomoto Co Inc | 微生物由来トランスグルタミナーゼの改変方法 |
CN105441404A (zh) * | 2015-12-08 | 2016-03-30 | 浙江科技学院 | ω-转氨酶突变体及其编码基因和制备方法 |
CN105950581A (zh) * | 2016-06-21 | 2016-09-21 | 浙江科技学院 | 一种引入二硫键的ω-转氨酶突变体及其应用 |
CN107058256A (zh) * | 2017-05-04 | 2017-08-18 | 浙江科技学院 | ω‑转氨酶突变体及其制备方法和应用 |
CN108913671A (zh) * | 2018-06-15 | 2018-11-30 | 浙江科技学院 | 一种ω-转氨酶突变体及其应用 |
CN110144335A (zh) * | 2019-04-26 | 2019-08-20 | 浙江科技学院 | 一种ω-转氨酶双突变体及其应用 |
CN110229805A (zh) * | 2019-06-28 | 2019-09-13 | 浙江科技学院 | 一种通过序列一致性制备的谷氨酸脱羧酶突变体及其应用 |
CN111549011A (zh) * | 2020-06-03 | 2020-08-18 | 重庆迪维斯生物科技有限公司 | 来源于土曲霉菌的转氨酶突变体及其应用 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7202070B2 (en) * | 2000-10-31 | 2007-04-10 | Biocatalytics, Inc. | Method for reductive amination of a ketone using a mutated enzyme |
EP2641972A1 (de) * | 2012-03-22 | 2013-09-25 | Universität Graz | Verfahren zur asymmetrischen Aminierung von Ketonen unter Verwendung von omega-Transamminasen in organischen Lösungsmitteln |
WO2016075082A1 (en) * | 2014-11-10 | 2016-05-19 | Sandoz Ag | Stereoselective reductive amination of alpha-chiral aldehydes using omega-transaminases for the synthesis of precursors of pregabalin and brivaracetam |
CN109370998B (zh) * | 2018-11-30 | 2020-08-04 | 江南大学 | 一种催化效率提高的ω-转氨酶突变体I215F |
CN111235127B (zh) * | 2020-04-29 | 2020-08-14 | 凯莱英医药集团(天津)股份有限公司 | 转氨酶突变体及其应用 |
CN111826362B (zh) * | 2020-07-13 | 2022-05-10 | 李元源 | 一种ω-转氨酶突变体、基因及应用 |
-
2020
- 2020-12-04 CN CN202011415007.1A patent/CN112481230B/zh active Active
- 2020-12-04 CN CN202111331763.0A patent/CN114107241B/zh active Active
- 2020-12-04 CN CN202111345072.6A patent/CN114181918B/zh active Active
-
2021
- 2021-12-06 US US17/543,608 patent/US20220177933A1/en active Pending
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002253272A (ja) * | 2000-08-17 | 2002-09-10 | Ajinomoto Co Inc | 微生物由来トランスグルタミナーゼの改変方法 |
CN105441404A (zh) * | 2015-12-08 | 2016-03-30 | 浙江科技学院 | ω-转氨酶突变体及其编码基因和制备方法 |
CN105950581A (zh) * | 2016-06-21 | 2016-09-21 | 浙江科技学院 | 一种引入二硫键的ω-转氨酶突变体及其应用 |
CN107058256A (zh) * | 2017-05-04 | 2017-08-18 | 浙江科技学院 | ω‑转氨酶突变体及其制备方法和应用 |
CN108913671A (zh) * | 2018-06-15 | 2018-11-30 | 浙江科技学院 | 一种ω-转氨酶突变体及其应用 |
CN110144335A (zh) * | 2019-04-26 | 2019-08-20 | 浙江科技学院 | 一种ω-转氨酶双突变体及其应用 |
CN110229805A (zh) * | 2019-06-28 | 2019-09-13 | 浙江科技学院 | 一种通过序列一致性制备的谷氨酸脱羧酶突变体及其应用 |
CN111549011A (zh) * | 2020-06-03 | 2020-08-18 | 重庆迪维斯生物科技有限公司 | 来源于土曲霉菌的转氨酶突变体及其应用 |
Non-Patent Citations (4)
Title |
---|
CHUN-YAN LIU: "Improving thermostability of (R)-selective amine transaminase from Aspergillus terreus by evolutionary coupling saturation mutagenesis", BIOCHEMICAL ENGINEERING JOURNAL, pages 4 - 11 * |
DONG-FANG XIE: "Construction of stabilized (R)-selective amine transaminase from Aspergillus terreus by consensus mutagenesis", JOURNAL OF BIOTECHNOLOGY, pages 8 * |
FANGFANG FAN: "Turning thermostability of Aspergillus terreus (R)-selective transaminase At-ATA by synthetic shuffling", JOURNAL OF BIOTECHNOLOGY, pages 66 * |
NCBI: "UUA81761.1", GENBANK, pages 1 - 2 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117126824A (zh) * | 2022-05-18 | 2023-11-28 | 江苏美科生物科技有限公司 | 一种转氨酶的突变体及其在制备西他列汀中间体生产中的应用 |
Also Published As
Publication number | Publication date |
---|---|
CN114107241B (zh) | 2023-12-08 |
CN114107241A (zh) | 2022-03-01 |
CN112481230B (zh) | 2021-12-07 |
CN114181918B (zh) | 2023-09-15 |
CN112481230A (zh) | 2021-03-12 |
US20220177933A1 (en) | 2022-06-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN112481230B (zh) | 一种通过DNA合成改组组合突变获得的ω-转氨酶突变体及应用 | |
CN111621482B (zh) | 一种草铵膦脱氢酶突变体、基因工程菌及一锅法多酶同步定向进化方法 | |
CN112553178B (zh) | 热稳定性和活性增强的烟酰胺核糖激酶突变体及其编码基因和应用 | |
CN108913671B (zh) | 一种ω-转氨酶突变体及其应用 | |
WO2019169695A1 (zh) | 一种慢生根瘤菌单加氧酶及其在制备手性亚砜中的应用 | |
CN112795546B (zh) | 一种具有高逆转录效率的耐高温逆转录酶突变体及其应用 | |
CN114317507B (zh) | 腈水合酶突变体及其应用 | |
CN111808829B (zh) | 一种γ-谷氨酰甲胺合成酶突变体及其应用 | |
WO2022016597A1 (zh) | 环己烯甲酸酯水解酶及其突变体、编码基因、表达载体、重组菌与应用 | |
CN107937422B (zh) | 一种panD突变基因、基因工程及其在催化生产β-丙氨酸中的应用 | |
CN110408604B (zh) | 底物亲和力和辅酶亲和力提高的甲酸脱氢酶突变体 | |
CN111518783A (zh) | 新型重组(R)-ω-转氨酶、突变体及其在制备西他列汀中的应用 | |
CN113430181A (zh) | 一种来源亚洲象肠道宏基因组的细菌漆酶及其基因 | |
CN114672525A (zh) | N-乙酰基-5-甲氧基色胺的生物合成方法及其应用 | |
CN111133105B (zh) | D型氨基酸脱氢酶 | |
CN113621589B (zh) | 醛酮还原酶KmAKR突变体、工程菌及其应用 | |
CN114958893A (zh) | 一种乳猪高温教槽料制备所需的乳糖酶的构建方法 | |
CN112391373A (zh) | 一种高产γ-氨基丁酸的谷氨酸脱羧酶GADZ1及其基因和应用 | |
CN114672524B (zh) | 一种催化非天然氨基酸衍生物的双功能血红素蛋白 | |
CN112795549A (zh) | 一种逆转录酶突变体 | |
CN114250206B (zh) | 甲基转移酶突变体、重组载体、重组工程菌及其应用 | |
CN116254253B (zh) | 一种通过dna合成改组组合突变获得的谷氨酸脱羧酶突变体及应用 | |
CN114645030B (zh) | 一种ω-转氨酶突变体及其在制备西塞卡纳药物中间体的应用 | |
CN114196642B (zh) | 谷氨酸脱氢酶变体及其在制备l-氨基酸中的应用 | |
CN113444700B (zh) | 一种提高乙酰丙酮合成效率的乙酰丙酮裂解酶突变体、核苷酸、表达载体、重组菌及应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |